Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer

Autor: H. Barton Grossman, Juan Palou, Molly A. Ingersoll, Antonia Vlahou, Marta Sanchez-Carbayo, John A. Taylor, Bas W.G. van Rhijn, Wassim Kassouf, M´Liss A. Hudson, Peter J. Goebell, T. Todenhöfer, Bernd J. Schmitz-Dräger, Ashish Chandra, Thomas Behrens, Ashish M. Kamat, Beate Pesch
Přispěvatelé: MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Biomedical Research Foundation of the Academy of Athens, Department of Urology, University of Connecticut (UCONN), Department of Cardiology Ochsner Clinic Foundation, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Immunobiologie des Cellules Dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, McGill University = Université McGill [Montréal, Canada], Protein Research Unit Ruhr within Europe (PURE), Ruhr-Universität Bochum [Bochum], Guy's and St Thomas' Hospital [London], Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), servicio de urologia, Fundación Puigvert, CIC BioGUNE, CIC Spain, urology 24, Schön Klinik Nürnberg/Fürth, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Zdroj: Urologic Oncology: Seminars and Original Investigations
Urologic Oncology: Seminars and Original Investigations, Elsevier, 2014, 32 (7), pp.1069-1077. ⟨10.1016/j.urolonc.2014.06.017⟩
Urologic Oncology: Seminars and Original Investigations, 2014, 32 (7), pp.1069-1077. ⟨10.1016/j.urolonc.2014.06.017⟩
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2014.06.017⟩
Popis: This article reflects and summarizes discussions held at the 10th Meeting of the International Bladder Cancer Network (IBCN e.V.), Nijmegen, The Netherlands, 20—22.9.2012.; International audience; OBJECTIVE: Diagnosis and surveillance of high risk non muscle-invasive bladder cancer (NMIBC) represent specific challenges to urologists. In contrast to low/intermediate risk tumors, these tumors recur more frequently. A significant number will eventually progress to muscle-invasive bladder cancer, a life threatening disease requiring extensive therapeutic efforts. Although clinical risk factors have been identified that may predict tumor recurrence and progression, additional biomarkers are desperately needed to improve tumor diagnosis and guide clinical management of these patients. In this article, the role of molecular urine markers in the management of high risk NMIBC is analyzed.METHODS:In this context, several potential indications (diagnostic, prognostic, predictive) were identified and the requirements for molecular markers were defined. In addition, current knowledge within the different indications was summarized.RESULTS:Significant progress has been made in the last decade studying the impact of molecular urine markers in patients with high risk NMIBC.CONCLUSIONS:Although we may not be ready for the inclusion of molecular markers in clinical decision-making, and many questions remain unanswered, recent studies have identified situations in which the use of molecular markers in particular in high grade tumors may prove beneficial for patient diagnosis and surveillance.
Databáze: OpenAIRE
Externí odkaz: